Skip to main content
Erschienen in: Annals of Surgical Oncology 2/2013

01.02.2013 | Healthcare Policy and Outcomes

Treatment Trends and Predictors of Adjuvant and Neoadjuvant Therapy for Gastric Adenocarcinoma in the United States

verfasst von: Karen L. Sherman, MD, Ryan P. Merkow, MD, Karl Y. Bilimoria, MS, MD, C. Edward Wang, PhD, Mary F. Mulcahy, MD, Al B. Benson, MD, David J. Bentrem, MS, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Over the last decade, evidence suggesting the benefits of adjuvant therapy in the treatment of stage IB–III gastric adenocarcinoma has emerged, though the influence of these clinical trials and current treatment patterns is unknown. Our objectives were (1) to assess changes in gastric adenocarcinoma treatment over time, (2) to identify predictors of neoadjuvant or postoperative adjuvant therapy use, and (3) to identify factors associated with neoadjuvant therapy use.

Methods

Patients with stage IB–III gastric adenocarcinoma diagnosed between 1998 and 2007 in the National Cancer Data Base who underwent surgical resection were selected. Models were developed to identify factors associated with treatment.

Results

We identified 30,448 patients diagnosed with stage IB–III gastric adenocarcinoma who underwent surgical resection. Rates of systemic therapy receipt (either before or after surgery) increased by 71 % from 1998 to 2007 (p < 0.001). Receipt of neoadjuvant therapy receipt increased by 237 % over 10 years (p < 0.001), with the highest rate of increase seen at high-volume academic centers. American Joint Committee on Cancer (AJCC) stage and age were the strongest predictors of pre- or postoperative systemic therapy among surgical patients. Neoadjuvant therapy receipt was most strongly predicted by tumor location in the gastric cardia.

Conclusions

Treatment trends over the past decade reflect rapid adoption of evidence from randomized controlled trials by increased receipt of pre- and postoperative systemic therapy in the treatment of stage IB–III gastric adenocarcinoma. Although age and AJCC stage are strongly associated with receiving systemic adjuvant therapy, tumor location is the most significant predictor of neoadjuvant therapy.
Literatur
1.
Zurück zum Zitat Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12:354–62.PubMed Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12:354–62.PubMed
2.
Zurück zum Zitat Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol. 2006;20:633–49.PubMedCrossRef Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol. 2006;20:633–49.PubMedCrossRef
3.
Zurück zum Zitat Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 1993;11:1441–7.PubMed Hermans J, Bonenkamp JJ, Boon MC, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 1993;11:1441–7.PubMed
4.
Zurück zum Zitat Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.PubMedCrossRef Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.PubMedCrossRef
5.
Zurück zum Zitat Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol. 2002;9:278–86.PubMedCrossRef Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol. 2002;9:278–86.PubMedCrossRef
6.
Zurück zum Zitat Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22:2774–80.PubMedCrossRef Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22:2774–80.PubMedCrossRef
7.
Zurück zum Zitat Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.PubMedCrossRef Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.PubMedCrossRef
8.
Zurück zum Zitat Van Cutsem E, Dicato M, Arber N, et al. The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005. Ann Oncol. 2006;17(Suppl 6):13–8. Van Cutsem E, Dicato M, Arber N, et al. The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005. Ann Oncol. 2006;17(Suppl 6):13–8.
9.
Zurück zum Zitat Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.PubMedCrossRef Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.PubMedCrossRef
10.
Zurück zum Zitat Cunningham D, Allen WH, Stenning SP, et al. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). 2005 ASCO Annual Meeting Proceedings. J Clin Oncol. 2005;23(16S, Part I of II, June 1 Supplement):4001. Cunningham D, Allen WH, Stenning SP, et al. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). 2005 ASCO Annual Meeting Proceedings. J Clin Oncol. 2005;23(16S, Part I of II, June 1 Supplement):4001.
11.
12.
Zurück zum Zitat Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–90.PubMedCrossRef Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683–90.PubMedCrossRef
13.
Zurück zum Zitat World Health Organization. International classification of disease for oncology. 2nd ed. Geneva: World Health Organization; 1990. World Health Organization. International classification of disease for oncology. 2nd ed. Geneva: World Health Organization; 1990.
14.
Zurück zum Zitat World Health Organization. International classification of disease for oncology. 3rd ed. Geneva: World Helath Organization; 2000. World Health Organization. International classification of disease for oncology. 3rd ed. Geneva: World Helath Organization; 2000.
15.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRef Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRef
16.
Zurück zum Zitat Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.PubMedCrossRef Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.PubMedCrossRef
17.
Zurück zum Zitat Greene FL, Page DL, Fleming ID, et al., editors. AJCC cancer staging manual. 6th ed. New York: Springer; 2002. Greene FL, Page DL, Fleming ID, et al., editors. AJCC cancer staging manual. 6th ed. New York: Springer; 2002.
19.
Zurück zum Zitat Commission on Cancer. Facility oncology registry data standards. Chicago: Commission on Cancer; 2004. Commission on Cancer. Facility oncology registry data standards. Chicago: Commission on Cancer; 2004.
21.
Zurück zum Zitat Balas EA, Boren SA. Managing clinical knowledge for health care improvement. In: Bemmel J, Mccray AT, editors. Yearbook of medical informatics, 2000: patient-centered systems. Stuttgart: Schattauer Verlagsgesellschaft; 2000. p. 65–70. Balas EA, Boren SA. Managing clinical knowledge for health care improvement. In: Bemmel J, Mccray AT, editors. Yearbook of medical informatics, 2000: patient-centered systems. Stuttgart: Schattauer Verlagsgesellschaft; 2000. p. 65–70.
22.
Zurück zum Zitat Coburn NG, Guller U, Baxter NN, et al. Adjuvant therapy for resected gastric cancer—rapid, yet incomplete adoption following results of Intergroup 0116 Trial. Int J Radiat Oncol Biol Phys. 2008;70:1073–80.PubMedCrossRef Coburn NG, Guller U, Baxter NN, et al. Adjuvant therapy for resected gastric cancer—rapid, yet incomplete adoption following results of Intergroup 0116 Trial. Int J Radiat Oncol Biol Phys. 2008;70:1073–80.PubMedCrossRef
23.
Zurück zum Zitat Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246:173–80.PubMedCrossRef Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246:173–80.PubMedCrossRef
24.
Zurück zum Zitat Bilimoria KY, Bentrem DJ, Linn JG, et al. Utilization of total thyroidectomy for papillary thyroid cancer in the United States. Surgery. 2007;142:906–13.PubMedCrossRef Bilimoria KY, Bentrem DJ, Linn JG, et al. Utilization of total thyroidectomy for papillary thyroid cancer in the United States. Surgery. 2007;142:906–13.PubMedCrossRef
25.
Zurück zum Zitat Bilimoria KY, Balch CM, Bentrem DJ, et al. Complete lymph node dissection for sentinel node–positive melanoma: assessment of practice patterns in the United States. Ann Surg Oncol. 2008;15:1566–76.PubMedCrossRef Bilimoria KY, Balch CM, Bentrem DJ, et al. Complete lymph node dissection for sentinel node–positive melanoma: assessment of practice patterns in the United States. Ann Surg Oncol. 2008;15:1566–76.PubMedCrossRef
26.
Zurück zum Zitat Merkow RP, Bilimoria KY, McCarter MD, Chow WB, Ko CY, Bentrem DJ. Use of multimodality neoadjuvant therapy for esophageal cancer in the United States: assessment of 987 hospitals. Ann Surg Oncol. 2012;19:357–64.PubMedCrossRef Merkow RP, Bilimoria KY, McCarter MD, Chow WB, Ko CY, Bentrem DJ. Use of multimodality neoadjuvant therapy for esophageal cancer in the United States: assessment of 987 hospitals. Ann Surg Oncol. 2012;19:357–64.PubMedCrossRef
27.
Zurück zum Zitat Steyerberg EW, Neville B, Weeks JC, Earle CC. Referral patterns, treatment choices, and outcomes in locoregional esophageal cancer: a population-based analysis of elderly patients. J Clin Oncol. 2007;25:2389–96.PubMedCrossRef Steyerberg EW, Neville B, Weeks JC, Earle CC. Referral patterns, treatment choices, and outcomes in locoregional esophageal cancer: a population-based analysis of elderly patients. J Clin Oncol. 2007;25:2389–96.PubMedCrossRef
28.
Zurück zum Zitat Hynes DM, Tarlov E, Durazo-Arvizu R, et al. Surgery and adjuvant chemotherapy use among veterans with colon cancer: insights from a California study. J Clin Oncol. 2010;28:2571–6.PubMedCrossRef Hynes DM, Tarlov E, Durazo-Arvizu R, et al. Surgery and adjuvant chemotherapy use among veterans with colon cancer: insights from a California study. J Clin Oncol. 2010;28:2571–6.PubMedCrossRef
29.
Zurück zum Zitat Hundahl SA, Menck HR, Mansour EG, Winchester DP. The National Cancer Data Base report on gastric carcinoma. Cancer. 1997;80:2333–41.PubMedCrossRef Hundahl SA, Menck HR, Mansour EG, Winchester DP. The National Cancer Data Base report on gastric carcinoma. Cancer. 1997;80:2333–41.PubMedCrossRef
30.
Zurück zum Zitat Dobie SA, Warren JL, Matthews B, Schwartz D, Baldwin LM, Billingsley K. Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population. Cancer. 2008;112:789–99.PubMedCrossRef Dobie SA, Warren JL, Matthews B, Schwartz D, Baldwin LM, Billingsley K. Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population. Cancer. 2008;112:789–99.PubMedCrossRef
31.
Zurück zum Zitat Dudeja V, Habermann EB, Zhong W, et al. Guideline recommended gastric cancer care in the elderly: insights into the applicability of cancer trials to real world. Ann Surg Oncol. 2011;18:26–33.PubMedCrossRef Dudeja V, Habermann EB, Zhong W, et al. Guideline recommended gastric cancer care in the elderly: insights into the applicability of cancer trials to real world. Ann Surg Oncol. 2011;18:26–33.PubMedCrossRef
32.
Zurück zum Zitat Al-Refaie WB, Tseng JF, Gay G, et al. The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Results from the National Cancer Data Base. Cancer. 2008;113:461–9.PubMedCrossRef Al-Refaie WB, Tseng JF, Gay G, et al. The impact of ethnicity on the presentation and prognosis of patients with gastric adenocarcinoma. Results from the National Cancer Data Base. Cancer. 2008;113:461–9.PubMedCrossRef
33.
Zurück zum Zitat Dudeja V, Gay G, Habermann EB, et al. Do hospital attributes predict guideline-recommended gastric cancer care in the United States? Ann Surg Oncol. 2012;19:365–72.PubMedCrossRef Dudeja V, Gay G, Habermann EB, et al. Do hospital attributes predict guideline-recommended gastric cancer care in the United States? Ann Surg Oncol. 2012;19:365–72.PubMedCrossRef
Metadaten
Titel
Treatment Trends and Predictors of Adjuvant and Neoadjuvant Therapy for Gastric Adenocarcinoma in the United States
verfasst von
Karen L. Sherman, MD
Ryan P. Merkow, MD
Karl Y. Bilimoria, MS, MD
C. Edward Wang, PhD
Mary F. Mulcahy, MD
Al B. Benson, MD
David J. Bentrem, MS, MD
Publikationsdatum
01.02.2013
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 2/2013
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2552-7

Weitere Artikel der Ausgabe 2/2013

Annals of Surgical Oncology 2/2013 Zur Ausgabe

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Gegen postoperative Darmmotilitätsstörung: Erster Kaffee schon im Aufwachraum

30.04.2024 DCK 2024 Kongressbericht

Nach einer Operation kann es zu einer vorübergehenden Störung der Darmmotilität kommen, ohne dass es eine mechanische Ursache gibt. Auf eine postoperative Darmmotilitätsstörung weist besonders hin, wenn Nahrung oral nicht toleriert wird.

Welche Übungen helfen gegen Diastase recti abdominis?

30.04.2024 Schwangerenvorsorge Nachrichten

Die Autorinnen und Autoren einer aktuellen Studie aus Griechenland sind sich einig, dass Bewegungstherapie, einschließlich Übungen zur Stärkung der Bauchmuskulatur und zur Stabilisierung des Rumpfes, eine Diastase recti abdominis postpartum wirksam reduzieren kann. Doch vieles ist noch nicht eindeutig belegt.

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.